Unavailable
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $PGEN
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/22/2024 | Neutral → Underweight | JP Morgan | |
5/23/2023 | Neutral | JP Morgan | |
11/18/2022 | $7.00 | Overweight | Cantor Fitzgerald |
Precigen Reports Full Year 2024 Financial Results and Business Updates
FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory MedicinePRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of August 28, 2024 data cutoffCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launchCompany ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending i
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
– Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serious conditions – – If approved, PRGN-2012 would be the first and only available FDA-approved therapy for eligible patients with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated surgeries – GERMANTOWN, Md., Feb. 25, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the US Food and Drug Administration (FDA) h
Precigen downgraded by JP Morgan
JP Morgan downgraded Precigen from Neutral to Underweight
JP Morgan initiated coverage on Precigen
JP Morgan initiated coverage of Precigen with a rating of Neutral
Cantor Fitzgerald initiated coverage on Precigen with a new price target
Cantor Fitzgerald initiated coverage of Precigen with a rating of Overweight and set a new price target of $7.00
SVP, IP Affairs Perez Jeffrey Thomas bought $50,000 worth of shares (58,823 units at $0.85), increasing direct ownership by 9% to 743,097 units (SEC Form 4)
4 - PRECIGEN, INC. (0001356090) (Issuer)
Director Kirk Randal J bought $19,999,999 worth of shares (23,529,411 units at $0.85) (SEC Form 4)
4 - PRECIGEN, INC. (0001356090) (Issuer)
Kirk Randal J bought $136,327 worth of shares (96,686 units at $1.41) (SEC Form 4)
4 - PRECIGEN, INC. (0001356090) (Issuer)
Director Kirk Randal J was granted 57,471 shares and converted options into 174,825 shares (SEC Form 4)
4 - PRECIGEN, INC. (0001356090) (Issuer)
Director Agee Nancy H was granted 32,471 shares, increasing direct ownership by 184% to 50,076 units (SEC Form 4)
4 - PRECIGEN, INC. (0001356090) (Issuer)
Director Gupta Vinita D was granted 36,206 shares and converted options into 87,412 shares, increasing direct ownership by 27% to 576,240 units (SEC Form 4)
4 - PRECIGEN, INC. (0001356090) (Issuer)
SEC Form 10-K filed by Precigen Inc.
10-K - PRECIGEN, INC. (0001356090) (Filer)
SEC Form 8-K filed by Precigen Inc.
8-K - PRECIGEN, INC. (0001356090) (Filer)
Precigen Inc. filed SEC Form 8-K: Other Events
8-K - PRECIGEN, INC. (0001356090) (Filer)
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
– Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden
Actym Therapeutics Appoints Thomas Smart as CEO
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HPV-driven disease with no FDA-approved therapeutic – GERMANTOWN, Md., March 28, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise awareness about recurrent respirator
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
GERMANTOWN, Md., Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357
Amendment: SEC Form SC 13D/A filed by Precigen Inc.
SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)
SEC Form SC 13D/A filed by Precigen Inc. (Amendment)
SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)
SEC Form SC 13G/A filed by Precigen Inc. (Amendment)
SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)